ADMA Biologics, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in ADMA Biologics, Inc. ("ADMA" or the "Company") (NASDAQ: ADMA) of a class action securities lawsuit.

The lawsuit seeks to recover losses on behalf of investors of ADMA Biologics, Inc. who were adversely affected if they purchased the Company's securities between August 9, 2024 and March 25, 2026, both dates inclusive (the "Class Period"). This action is pending in the United States District Court for the District of New Jersey.

ADMA investors should contact KSF Managing Partner Lewis Kahn toll-free at 1-833-538-3653 or via email ([email protected]), or visit https://www.ksfcounsel.com/cases/nasdaqgm-adma/ to learn more.

According to the Complaint, ADMA Biologics and certain of its executives are charged with failing to disclose material information in the Offering Documents, violating federal securities laws.

The alleged false and misleading statements and omissions include, but are not limited to, that: (i) the Company engaged in an undisclosed related party transaction; (ii) the Company used channel stuffing to create an appearance of revenue; (iii) the Company lacked adequate internal controls; (iv) as a result, Defendants' statements about the Company's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

When the true details entered the market, the lawsuit claims that investors suffered damages.

The case is Mazzarino v. ADMA Biologics, Inc., et al, No. 26-cv-04793.

If you invested in ADMA and suffered a loss during the relevant time frame, you have until August 10, 2026 to request that the Court appoint you as lead plaintiff; however, your ability to share in any recovery does not require that you serve as a lead plaintiff.